POM-V Prescription Required Companion Animal

BenazeVet 5 mg Tablets for Cats and Dogs

Active ingredient: Benazepril Hydrochloride

Form

Tablet

Species

Cats Dogs

Manufacturer

Elanco Europe Ltd

VMD MA No.

00879/5060

What it's used for

Dogs: Treatment of congestive heart failure. Cats: Reduction of proteinuria associated with chronic kidney disease

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Benazepril Hydrochloride

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

BenazeVet 5 mg Tablets for Cats and Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 18 Mar 2026.

Dogs:
Treatment of congestive heart failure.
Cats:
Reduction of proteinuria associated with chronic kidney disease

This veterinary medicinal product should be given orally once daily, with or without
food. The duration of treatment is unlimited.
This product is flavoured and is taken voluntarily by most dogs and cats.
If a tablet is divided into halves the remaining tablet portion should be given at the
next administration.
Dogs:
This veterinary medicinal product should be administered orally at a minimum dose
of 0.25 mg (range 0.25-0.5) benazepril hydrochloride/kg body weight once daily,
according to the following table:
BenazeVet 5 mgWeight of dog
(kg)
Standard
dose
Double
dose
>5 - 100.5 tablet1 tablet>10 - 201 tablet2 tablets

Revised: December 2025
MA split from NI Expiry following AN: 02082/2025
The dose may be doubled, still administered once daily, to a minimum dose of 0.5
mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary
surgeon.
Cats:
This veterinary medicinal product should be administered orally at a minimum dose
of 0.5 mg (range 0.5-1.0) benazepril hydrochloride/kg body weight once daily
according to the following table:
Weight of cat (kg)BenazeVet 5 mg 2.5 – 50.5 tablet>5 – 101 tablet

Do not use in known cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal
failure.
Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.
Do not use during pregnancy or lactation (section 4.7).

In double-blind clinical trials in dogs with congestive heart failure, the veterinary
medicinal product was well tolerated with an incidence of adverse reactions lower
than observed in placebo-treated dogs.
A small number of dogs may exhibit transient vomiting, incoordination or signs of
fatigue.
In rare occasions diarrhoea and anorexia have been reported in dogs.
In cats and dogs with chronic kidney disease, the product may increase plasma
creatinine concentrations at the start of therapy. A moderate increase in plasma
creatinine concentrations following administration of ACE inhibitors is compatible with
the reduction in glomerular hypertension induced by these agents, and is therefore
not necessarily a reason to stop therapy in the absence of other signs.
The veterinary medicinal product may increase food consumption and body weight in
cats.
Emesis, anorexia, dehydration, lethargy and diarrhoea have been reported in rare
occasions in cats.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Revised: December 2025
MA split from NI Expiry following AN: 02082/2025

None.

Revised: December 2025
MA split from NI Expiry following AN: 02082/2025

Special precautions for use in animals
No evidence of renal toxicity of the veterinary medicinal product has been observed
(in dogs or cats) during clinical trials, however, as is routine in cases of chronic kidney
disease, it is recommended to monitor plasma creatinine, urea and erythrocyte counts
during therapy.
The efficacy and safety of the veterinary medicinal product has not been established
in dogs and cats below 2.5 kg body weight.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
The product may cause hypotension after ingestion. To avoid accidental ingestion,
particularly by a child, unused part-tablets should be returned to the open blister
space and inserted back into the carton. In case of accidental ingestion, seek medical
advice immediately and show the package leaflet or the label to the physician.
Angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn
child during pregnancy in humans. Pregnant women should therefore take special
care to avoid accidental ingestion, including hand to mouth contact.
Wash hands after use.

In dogs with congestive heart failure, the veterinary medicinal product has been given
in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary
medicinal products without demonstrable adverse interactions.
In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal
function. The combination of the veterinary medicinal product and other anti-
hypertensive agents (e.g. calcium channel blockers, or diuretics),
anaesthetics or sedatives may lead to additive hypotensive effects. Therefore,
concurrent use of NSAIDs or other medications with a hypotensive effect should be
considered with care. Renal function and signs of hypotension (lethargy, weakness
etc) should be monitored closely and treated as necessary. Interactions with
potassium preserving diuretics like spironolactone, triamterene or amiloride cannot
be ruled out. It is recommended to monitor plasma potassium levels when using the
veterinary medicinal product in combination with a potassium sparing diuretic
because of the risk of hyperkalaemia.

Do not store above 25 °C.
Each time an unused half tablet is stored, it should be returned to the open blister
space, inserted back into the cardboard box and kept in a safe place out of the sight
and reach of children.

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.